首页 社会内容详情
环球ug代理开户:No major delays in companies’ IPO plans

环球ug代理开户:No major delays in companies’ IPO plans

分类:社会

网址:

SEO查询: 爱站网 站长工具

点击直达

Telegram美国群www.tel8.vip)是一个Telegram群组分享平台。Telegram美国群包括Telegram美国群、telegram群组索引、Telegram群组导航、新加坡telegram群组、telegram中文群组、telegram群组(其他)、Telegram 美国 群组、telegram群组爬虫、电报群 科学上网、小飞机 怎么 加 群、tg群等内容。Telegram美国群为广大电报用户提供各种电报群组/电报频道/电报机器人导航服务。

Like most of its emerging-market peers, Malaysia has been suffering from a persistent sell-off in its equity market since the Fed made its third interest rate hike in June this year, raising it by 75 basis points – the most aggressive hike since 1994.

KUALA LUMPUR: Bursa Malaysia Bhd does not foresee delays in companies’ listing plans in 2022 despite a risk-off environment sparked by a hawkish US Federal Reserve (Fed) and external headwinds like the Ukraine-Russia war.

Instead, it anticipated the local bourse to see 37 initial public offerings (IPOs) in 2022 against 30 in 2021, primarily driven by a higher number of listings on the ACE Market following the reopening of the economy.

“Unless an IPO is large enough to warrant an international offering, we do not foresee any major delays in companies’ listing plans, as there is ample liquidity in our market to support purely domestic offerings,” a spokesman of Bursa Malaysia told Bernama recently.

The exchange operator said from Jan 1 to July 13, the local bourse saw 20 new listings, raising about RM2.3bil.

“The additional market capitalisation contributed by the 20 companies listed is RM7.3bil (up to July 13, 2022), and the IPO pipeline for the rest of the year remains strong,” it said.

Based on the number of IPOs approved and awaiting their listing and the number of exposure draft prospectuses on both Bursa Malaysia and the Securities Commission Malaysia’s (SC) websites, at least five more listings are expected to take place by year-end.

,

环球ug代理开户www.ugbet.us)开放环球UG代理登录网址、会员登录网址、环球UG会员注册、环球UG代理开户申请、环球UG电脑客户端、环球UG手机版下载等业务。

,

UMediC Group Bhd made a strong debut on the ACE Market at 50 sen per share on Tuesday – a 56.25% premium from its IPO price of 32 sen.

The medical device manufacturer’s counter closed at 44 sen, resulting in a market capitalisation of RM164.52mil.

Moving forward, the domestic investors’ appetite for IPOs would remain strong for the rest of the year as demonstrated by the level of oversubscription for most IPOs.

Businesses are expected to rebound on pent-up demand following the pandemic, and the reopening of borders will encourage spending.

“Hence, we believe the outlook for IPOs remains encouraging, as the equity capital market provides companies with access to funds for growth and recovery from the impact brought about by the Covid-19 pandemic.

“We are optimistic that the vibrancy and momentum of new IPOs on Bursa Malaysia will remain throughout 2022, particularly in the key promoted areas of technology, consumer, healthcare, halal and/or environmental, social and corporate governance (ESG)-compliant businesses,” the spokesman added.

Like most of its emerging-market peers, Malaysia has been suffering from a persistent sell-off in its equity market since the Fed made its third interest rate hike in June this year, raising it by 75 basis points – the most aggressive hike since 1994.

 当前暂无评论,快来抢沙发吧~

发布评论